Global Influenza Drug Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 960.55 Billion |
 Market Size (Forecast Year) |
USD 1,084.07 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Influenza Drug Market, By Type (Influenza A, Influenza B, and Influenza C), Treatment (Vaccines and Drugs), Route of Administration (Oral, Intramuscular, Intradermal, Intranasal, and Intravenous), Age (Pediatrics and Adults), End User (Hospitals, and Home Care), Distribution Channel (Direct Tenders and Retail Sales) - Industry Trends and Forecast to 2031.
Influenza Drug Market Analysis and Size
One driving factor for the global influenza drug market is the rising awareness regarding influenza and its potential complications, which is fueling an increased demand for preventive and therapeutic solutions. However, a notable challenge is the presence of generic versions of influenza drugs, leading to price pressures and potentially shrinking profit margins for manufacturers. Despite this, an opportunity exists in the development of novel and more effective drugs to address emerging strains of the influenza virus, providing a competitive advantage. Nevertheless, a persistent challenge is the necessity for ongoing research and development efforts to match the evolving nature of the influenza virus and its tendency to develop resistance to current treatments.
Data Bridge Market Research analyzes that the global influenza drug market is growing with a CAGR of 6.5% in the forecast period of 2024 to 2031 and is expected to reach USD 14.22 billion by 2031 from USD 8.73 billion in 2023. The rising prevalence of various types of cancer is expected to drive the market’s expansion.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable 2015-2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Type (Influenza A, Influenza B, and Influenza C), Treatment (Vaccines, Drugs), Route of Administration (Oral, Intramuscular, Intradermal, Intranasal, and Intravenous), Age (Pediatrics and Adults), End User (Hospitals, and Home Care), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa |
|
Market Players Covered |
GSK plc., Sanofi S.A., CSL, Astrazeneca Plc, F. Hoffmann-La Roche Ltd , Viatris Inc., Abbott, Amneal Pharmaceuticals LLC., AbbVie Inc BioCryst Pharmaceutucals, Inc., Lupin, Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, Cipla Inc., Shionogi & Co., Ltd. , Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and NATCO Pharma Limited, and Alvogen, among others |
Market Definition
Influenza drugs are medications created to either prevent or treat the flu, a contagious respiratory sickness. They include antiviral drugs that focus on the flu virus itself, as well as drugs that help relieve symptoms like fever, cough, and congestion. These medications are essential for handling and lessening the impact of flu outbreaks, particularly during times of widespread transmission or pandemics.
Global Influenza Drug Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Increasing Prevalence Rate of Influenza
The global influenza drugs market is experiencing a significant boost in growth due to the increasing prevalence of viral infections worldwide. The prevalence rate of influenza continues to underscore the critical need for advancements in influenza drugs and vaccines. With the emergence of various strains and the constant threat of seasonal outbreaks, the market for influenza medications has witnessed significant growth. Among the key contributors to this expansion are the development and adoption of vaccines with different valency formulations. Quadrivalent vaccines, for instance, offer protection against four different influenza strains, providing broader coverage compared to their trivalent counterparts. These vaccines are available in various forms, including injection and nasal spray, catering to different preferences and needs. The quadrivalent injection offers a convenient and effective method of immunization, particularly for individuals seeking quick and reliable protection against influenza. On the other hand, the nasal spray formulation provides an alternative option, especially for those averse to needles. Additionally, trivalent vaccines remain essential in regions where specific strains are prevalent, ensuring targeted protection against circulating influenza viruses. By incorporating diverse valency options, including quadrivalent and trivalent formulations, the influenza drugs and vaccine market continues to evolve, offering comprehensive solutions to combat the spread of the disease and mitigate its impact on public health.
For instance,
- In October 2023, according to the article published by WHO, seasonal influenza presents a significant global health burden, with approximately a billion cases reported annually, including 3–5 million cases of severe illness. The impact is particularly severe in developing countries, where 99% of deaths in children under 5 years of age with influenza-related lower tract infections and due to which deaths occur in the range from 290,000 to 650,000 annually, highlighting the seriousness of the disease and its potential consequences, especially in vulnerable populations
- In November 2021, according to the article published by NCBI, influenza epidemics pose a significant public health threat, resulting in 290,000–650,000 deaths worldwide each year. However, the toll of influenza pandemics can be even more devastating. The A(H1N1) pandemic of 1918–1919, also known as the Spanish flu, stands as a stark reminder of the potential severity of influenza outbreaks. This pandemic resulted in an estimated 20–50 million deaths globally, making it one of the deadliest pandemics in history
In conclusion, the development and utilization of multi-valent influenza drugs and vaccines, such as quadrivalent formulations and alternative delivery methods like nasal sprays, are crucial steps towards effectively managing the prevalence of influenza. This multi-pronged approach not only enhances vaccination coverage but also contributes significantly to the growth of the influenza drug and vaccine market. Hence, as the global healthcare industry continues to prioritize health, the increasing prevalence of viral infections acts as a catalyst for advancements in treatment modalities, contributing to the sustained growth of the global influenza market.
- Government Initiatives and Vaccination Programs
Increased government initiatives and expanded vaccination programs play a pivotal role in driving growth within the influenza drug market by fostering the stimulating demand. As governments worldwide prioritize public health through comprehensive immunization strategies, pharmaceutical companies specializing in influenza drugs stand to benefit significantly. By actively participating in government initiatives, these companies gain access to lucrative contracts and procurement opportunities for supplying vaccines to national immunization programs. Moreover, engagement in vaccination programs allows pharmaceutical firms to showcase the efficacy and safety of their influenza drugs, enhancing their reputation and market visibility. As governments increasingly prioritize preparedness against seasonal influenza outbreaks and potential pandemics, the demand for innovative vaccines and therapeutics continues to rise. Companies that actively collaborate with government agencies, provide reliable supply chains, and demonstrate commitment to public health objectives are poised to capitalize on this growing market demand. By leveraging government partnerships and actively participating in vaccination programs, pharmaceutical companies can not only contribute to the global fight against influenza but also drive sustainable growth and expansion within the influenza drug market. . Governments also focusing on campaigns, emphasizing the importance of vaccination and adherence to prescribed treatment regimens, further driving the market's growth.
For instance,
- In December 2023, according to the article published by Centers for Disease Control and Prevention, U.S government start National Influenza Vaccination Week (NIVW) which is an annual observance in December to remind everyone 6 months and older that there’s still time to get vaccinated against flu. This annual event, held in December, aims to raise awareness about the importance of influenza vaccination and encourage more people, particularly those in high-risk groups, to get vaccinated. NIVW also provides resources and tools to healthcare providers to facilitate vaccination efforts across the country.
- In July 2023, according to the article published by Department of Health and Aged Care , the Australian government launched the National Immunization Program (NIP) to enhance access to influenza vaccines for eligible populations. The program provides free influenza vaccines to vulnerable groups, including children aged 6 months to less than 5 years, pregnant women, Aboriginal and Torres Strait Islander people, and individuals aged 65 years and older. This initiative aims to reduce the burden of influenza and its associated complications on public health.
- In March 2024, according to the article published by Ministry of Health & Family Welfare, Universal Immunization Program (UIP) (ongoing) launched in 1985, aims to provide vaccination against preventable diseases to all children across the country. In recent years, India has expanded its immunization efforts to include influenza vaccination for high-risk groups, such as healthcare workers, elderly individuals, and those with underlying health conditions. These vaccines, often available in both trivalent and quadrivalent formulations include antiviral which help safeguard against various strains of influenza, including Influenza type B. By incorporating these vaccines into the UIP, India aims to reduce the burden of influenza-related illness and contribute to the overall improvement of public health outcomes across the nation.
In conclusion, the increasing involvement in various government initiatives and vaccination programs significantly contributes to the overall revenue growth of pharmaceutical companies specializing in influenza drugs. By aligning with governmental priorities and actively participating in immunization strategies, these companies gain access to lucrative contracts and procurement opportunities, driving demand for their products. Moreover, engagement in vaccination programs allows pharmaceutical firms to demonstrate the efficacy and safety of their influenza drugs, enhancing their reputation and market visibility, thus attracting more customers globally and expected to act as a driver for market growth
Opportunity
- Integration of Telemedicine and Digital Health Solutions
Telemedicine offers healthcare providers the ability to remotely consult with patients, providing timely assessment and management of influenza symptoms without the need for face-to-face visits. This is particularly beneficial during influenza outbreaks, as it reduces the risk of virus transmission in healthcare settings and improves patient flow management.
Digital health solutions, such as mobile apps and wearable devices, are crucial for monitoring influenza symptoms and ensuring treatment adherence. These tools allow patients to track their symptoms, medication schedules, and overall health status, providing valuable data for remote monitoring by healthcare providers. Additionally, these digital tools empower patients to play a more active role in their healthcare, leading to improved treatment outcomes.
For Instance,
- In April 2022, according to an article published by BioMed Central Ltd, during a telehealth visit for a patient with influenza-like illness, a test threshold of around 25% and a treatment threshold of about 60% has been established. The inclusion of home influenza test outcomes decreased uncertainty and markedly reduced the necessity for in-person visits.
- In February 2022, according to an article published by MDPI, maternal influenza vaccination reduces illness and death in pregnant women and lowers risks for babies. A study on the "Influenza Vaccination Reminder Application" found it improved pregnant women's knowledge, attitudes, and intention to get vaccinated. The app, accessible on smartphones, offers valuable information, promoting vaccination and preventing missed opportunities.
- In September 2021, according to an article published by Johnson & Johnson Services, Inc., Cue Health is a digitally connected health monitoring system that begins with a rapid at-home diagnostic test. This test is linked to a telemedicine provider who can prescribe medication based on the test result. Originally focused on influenza, Cue Health is a rapid point-of-care diagnostics company.
- In October 2020, according to an article published by National Institutes of Health, Oseltamivir can reduce the duration of influenza symptoms, but it must be given within 48 hours of symptom onset. However, in primary care settings, only 20% of patients receive oseltamivir. This low rate is often due to false negative test results and patients seeking treatment after the 48-hour window. Direct-to-consumer (DTC) telemedicine could address these challenges by connecting patients with physicians 24 hours a day. This approach could help overcome delays in treatment and avoid exposing others to infection.
In conclusion, the integration of telemedicine and digital health in influenza diagnosis and treatment enhances healthcare accessibility, improves patient convenience, and enables more personalized and timely care. This integration also creates new opportunities for drug delivery and monitoring, enabling remote monitoring of patients' health status and facilitating the delivery of antiviral medications to remote or underserved areas. Overall, this integration represents a significant opportunity for advancing healthcare delivery in the management of influenza and other infectious diseases.
Restraint/Challenge
- Adverse Effect of Anti-Influenza Drugs
Influenza drugs, despite their efficacy in managing influenza infections, can act as a restraint for market growth due to the potential occurrence of adverse side effects. While common side effects like nausea, vomiting, headache, and diarrhea are generally tolerable, more severe reactions such as allergic responses, skin rash, or respiratory distress can deter patients from continued use. The rare occurrence of neuropsychiatric events, such as hallucinations or abnormal behavior, associated with antiviral medications like oseltamivir (Tamiflu) and zanamivir (Relenza), particularly in younger patients, raises concerns among healthcare providers and patients alike. These adverse effects may lead to hesitancy in prescribing or using influenza drugs, impacting market demand and growth.
For instance,
- In Feb 2020, according to the article published by NCBI, the adverse effects of neuraminidase inhibitors (NAIs) exhibit age-dependent variability, as observed in the findings reported by WebMD. In younger patients administered oseltamivir, a disproportionality in adverse reactions such as vomiting and hallucinations was detected. Conversely, older patients receiving peramivir exhibited adverse events including abnormal hepatic function, cardiac failure, shock, and cardio-arrest. Psychiatric disorders were most prevalent across both younger and older age groups, while gastrointestinal disorders predominated in adults administered oseltamivir
- In April 2024, according to the article published by Mayo Foundation for Medical Education and Research (MFMER), symptom such as nausea, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue, severe headache, skin rash, stiff neck and/or back, and sudden numbness and weakness in the arms and legs, can be associated with severe adverse reactions to certain drugs and supplements used to treat influenza. While influenza medications like oseltamivir (Tamiflu) and zanamivir (Relenza) are generally well-tolerated, in rare cases, individuals may experience severe allergic reactions or adverse effects.
In conclusion, while influenza drugs are effective in managing influenza infections, the occurrence of adverse side effects acts as a significant restraint on market growth. Common side effects such as nausea, vomiting, and headache, along with more severe reactions like allergic responses and neuropsychiatric events, can deter patients from using these medications. Concerns about safety and tolerability may lead to hesitancy among healthcare providers in prescribing influenza drugs and decrease patient adherence to treatment regimens.
Recent Developments
- In November 2023, AstraZeneca has announced a partnership and investment deal with Cellectis, a clinical-stage biotech company, to speed up the development of new therapies in areas with significant unmet medical needs such as oncology, immunology, and rare diseases. This collaboration will allow AstraZeneca to utilize Cellectis' gene editing technologies and manufacturing capabilities to create innovative cell and gene therapy products, enhancing AstraZeneca's portfolio in this field.
- In June 2023, GSK plc. and BELLUS Health Inc. announced today that GSK has finalized the acquisition of BELLUS, a biopharmaceutical company dedicated to improving the lives of patients with refractory chronic cough (RCC). This acquisition will enhance GSK's portfolio by adding BELLUS's expertise in refractory chronic cough (RCC) treatment, strengthening its position in addressing unmet medical needs in this area.
- In June 2023, Sanofi hosted a Vaccines Investor Event focusing on its pipeline, showcasing how its strategy is backed by vaccines R&D. The company aims for sustained growth in the vaccines business through core franchises in influenza, meningitis, and pediatric vaccines, along with a best-in-class RSV franchise to protect infants, toddlers, and older adults. This event will help Sanofi highlight its strategic focus on vaccines R&D and core franchises, showcasing its potential for sustained growth in the vaccines business.
- In November 2022, CSL has announced that its subsidiary, CSL Seqirus, has signed a collaboration and licensing agreement with Arcturus Therapeutics Holdings Inc to utilize their advanced self-amplifying mRNA (sa-mRNA) vaccine platform technology in the later stages of development. This collaboration will enable CSL Seqirus to leverage Arcturus Therapeutics' advanced sa-mRNA vaccine platform technology, potentially enhancing CSL's vaccine development capabilities.
- In May 2022, GSK plc announced a definitive agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company. The acquisition involves a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. This acquisition will strengthen GSK's vaccine pipeline by incorporating Affinivax's innovative MAPS technology, enhancing its ability to develop next-generation vaccines for various infectious diseases.
- In January 2022, Natco Pharma Limited has recently announced the signing of a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) in Switzerland. The MPP had previously acquired the license from Merck Sharp & Dohme Corp. (MSD) in the USA for the same purpose. This agreement with the Medicines Patent Pool will enable Natco Pharma Limited to expand its access to important medicines and enhance its ability to provide affordable healthcare solutions to a broader population.
- In January 2022, NATCO Pharma Inc. USA, a wholly owned subsidiary of NATCO Pharma Limited, has finalized the acquisition of Dash Pharmaceuticals LLC, based in New Jersey. Following this transaction, Dash will operate as a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO.
Global Influenza Drug Market Scope
The global Influenza drug market is segmented into six notable segments based on type, treatment, route of administration, age, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Influenza A
- Influenza B
- Influenza C
On the basis of type, the market is segmented into Influenza A, Influenza B and Influenza C.
Treatment
- Vaccines
- Drugs
On the basis of treatment, the market is segmented into vaccines and drugs.
Route of Administration
- Oral
- Intramuscular
- Intradermal
- Intranasal
- Intravenous
On the basis of route of administration, the market is segmented into oral, intramuscular, intradermal, intranasal, and intravenous.
Age
- Pediatrics
- Adults
On the basis of age, the market is segmented into pediatrics and adults.
End User
- Hospitals
- Homecare
On the basis of end user, the market is segmented into hospitals and homecare.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tenders and retail sales.
Global Influenza Drug Market Regional Analysis/Insights
The global Influenza drug market is analyzed, and market size insights and trends are provided by based on type, treatment, route of administration, age, end user, and distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Germany, Spain, Italy, France, Russia, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa.
North America is expected to dominate the market due to due to its advanced healthcare infrastructure, well-equipped hospitals, clinics, and home care centers, which ensures quality care for patients.
The U.S. is expected to dominate in the North America market due to its high prevalence of influenza cases, strong healthcare infrastructure, robust pharmaceutical industry, and high public awareness about influenza prevention. U.K. is expected to dominate in the Europe market due to its advanced healthcare system, high vaccination coverage, and proactive government initiatives to combat influenza outbreaks. Japan is expected to dominate in the Asia-Pacific market due to its high healthcare standards, advanced research and development capabilities, and a large elderly population that is particularly vulnerable to influenza.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Influenza Drug Market Share Analysis
The global influenza drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the global influenza drug market.
Some of the major players operating in the global influenza drug market are GSK plc., Sanofi S.A., CSL, Astrazeneca Plc, F. Hoffmann-La Roche Ltd , Viatris Inc., Abbott, Amneal Pharmaceuticals LLC., AbbVie Inc BioCryst Pharmaceutucals, Inc., Lupin, Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, Cipla Inc., Shionogi & Co., Ltd. , Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and NATCO Pharma Limited, and Alvogen, among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL INFLUENZA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE RATE OF INFLUENZA
5.1.2 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
5.1.3 ADVANCEMENTS IN MEDICAL RESEARCH AND TECHNOLOGY
5.1.4 CONTINOUS LAUNCHES OF THE NEW DRUGS AND VACCINE
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECT OF ANTI-INFLUENZA DRUGS
5.2.2 COUNTERFEIT OF DRUG IN PHARMACEUTICAL INDUSTRY
5.3 OPPORTUNITIES
5.3.1 INTEGRATION OF TELEMEDICINE AND DIGITAL HEALTH SOLUTIONS
5.3.2 DEVELOPMENT OF COMBINATION THERAPIES
5.3.3 ADVANCING UNIVERSAL VACCINES
5.4 CHALLENGES
5.4.1 EMERGENCE OF DRUG RESISTANT STRAINS
5.4.2 INEFFICIENCY IN THE SUPPLY CHAIN OF VACCINE
6 GLOBAL INFLUENZA DRUG MARKET, BY TYPE
6.1 OVERVIEW
6.2 INFLUENZA A
6.3 INFLUENZA B
6.4 INFLUENZA C
7 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 VACCINES
7.3 DRUGS
8 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.3 INTRAMUSCULAR
8.4 INTRADERMAL
8.5 INTRANASAL
8.6 INTRAVENOUS
9 GLOBAL INFLUENZA DRUG MARKET, BY AGE
9.1 OVERVIEW
9.2 PEDIATRICS
9.3 ADULTS
10 GLOBAL INFLUENZA DRUG MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 HOMECARE
11 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 GLOBAL INFLUENZA DRUG MARKET, BY REGION
12.1 OVERVIEW
12.2 NORTH AMERICA
12.2.1 U S
12.2.2 MEXICO
12.2.3 CANADA
12.3 EUROPE
12.3.1 U.K.
12.3.2 GERMANY
12.3.3 SPAIN
12.3.4 ITALY
12.3.5 FRANCE
12.3.6 RUSSIA
12.3.7 NETHERLAND
12.3.8 TURKEY
12.3.9 SWITZERLAND
12.3.10 BELGIUM
12.3.11 REST OF EUROPE
12.4 ASIA-PACIFIC
12.4.1 JAPAN
12.4.2 CHINA
12.4.3 SOUTH KOREA
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 MALAYSIA
12.4.7 THAILAND
12.4.8 INDONESIA
12.4.9 SINGAPORE
12.4.10 PHILIPPINES
12.4.11 REST OF ASIA-PACIFIC
12.5 SOUTH AMERICA
12.5.1 BRAZIL
12.5.2 ARGENTINA
12.5.3 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 U.A.E.
12.6.3 SAUDI ARABIA
12.6.4 EGYPT
12.6.5 ISRAEL
12.6.6 REST OF MIDDLE EAST AND AFRICA
13 GLOBAL INFLUENZA DRUG MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3 COMPANY SHARE ANALYSIS: EUROPE
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 GSK PLC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 SANOFI
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 CSL
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 ASTRAZENECA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 F. HOFFMANN-LA ROCHE LTD.
15.5.1 COMPANY SNAPSHOT
15.5.1 REVENUE ANALYSIS
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 ABBVIE INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ALVOGEN
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 AMNEAL PHARMACEUTICALS LLC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 BIOCRYST PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 CIPLA INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 DAIICHI SANKYO COMPANY, LIMITED
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MACLEODS PHARMACEUTICALS LTD.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 NATCO PHARMA LIMITED
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 SHIONOGI & CO., LTD.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 ZYDUS PHARMACEUTICALS, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 GLOBAL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 2 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 3 GLOBAL INFLUENZA B IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 GLOBAL INFLUENZA C IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 GLOBAL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 GLOBAL INFLUENZA A IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 9 GLOBAL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 10 GLOBAL TRIVALENTIN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 11 GLOBAL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 12 GLOBAL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 13 GLOBAL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 14 GLOBAL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 15 GLOBAL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 16 GLOBAL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 17 GLOBAL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 GLOBAL ORAL MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 GLOBAL INTRAMUSCULAR IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 GLOBAL INTRADERMAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 GLOBAL INTRANASAL IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 GLOBAL INTRAVENOUS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 GLOBAL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 24 GLOBAL PEDIATRICS MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 25 GLOBAL ADULTS IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 GLOBAL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 27 GLOBAL HOSPITALS IN GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 GLOBAL HOMECARE IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 29 GLOBAL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 30 GLOBAL DIRECT TENDER IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 GLOBAL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 33 GLOBAL INFLUENZA DRUG MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 56 U.S. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 57 U.S. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 58 U.S. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 59 U.S. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 60 U.S. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 61 U.S. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 67 MEXICO INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 MEXICO INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 69 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 70 MEXICO QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 71 MEXICO TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 72 MEXICO BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 73 MEXICO MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 74 MEXICO VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 75 MEXICO INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 76 MEXICO LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 77 MEXICO DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 78 MEXICO INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 79 MEXICO INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 80 MEXICO INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 81 MEXICO INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 82 MEXICO RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 89 CANADA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 90 CANADA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 91 CANADA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 92 CANADA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 93 CANADA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 94 CANADA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 CANADA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 96 CANADA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 97 CANADA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 98 CANADA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 99 EUROPE INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 100 EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 101 EUROPE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 102 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 103 EUROPE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 104 EUROPE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 105 EUROPE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 106 EUROPE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 107 EUROPE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 108 EUROPE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 109 EUROPE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 110 EUROPE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 111 EUROPE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 112 EUROPE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 113 EUROPE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 114 EUROPE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 115 EUROPE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 116 U.K. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 117 U.K. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 118 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 119 U.K. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 120 U.K. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 121 U.K. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 122 U.K. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 123 U.K. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 124 U.K. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 125 U.K. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 126 U.K. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 127 U.K. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 128 U.K. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 129 U.K. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 130 U.K. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 131 U.K. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 132 GERMANY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 133 GERMANY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 134 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 135 GERMANY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 136 GERMANY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 137 GERMANY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 138 GERMANY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 139 GERMANY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 140 GERMANY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 141 GERMANY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 142 GERMANY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 143 GERMANY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 144 GERMANY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 145 GERMANY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 146 GERMANY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 147 GERMANY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 148 SPAIN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 SPAIN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 150 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 151 SPAIN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 152 SPAIN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 153 SPAIN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 154 SPAIN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 155 SPAIN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 156 SPAIN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 157 SPAIN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 158 SPAIN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 159 SPAIN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 164 ITALY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 165 ITALY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 166 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 167 ITALY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 168 ITALY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 169 ITALY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 170 ITALY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 171 ITALY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 172 ITALY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 173 ITALY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 174 ITALY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 175 ITALY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 176 ITALY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 177 ITALY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 178 ITALY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 179 ITALY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 180 FRANCE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 FRANCE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 182 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 183 FRANCE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 184 FRANCE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 185 FRANCE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 186 FRANCE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 187 FRANCE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 188 FRANCE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 189 FRANCE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 190 FRANCE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 191 FRANCE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 192 FRANCE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 193 FRANCE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 194 FRANCE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 195 FRANCE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 196 RUSSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 197 RUSSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 198 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 199 RUSSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 200 RUSSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 201 RUSSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 202 RUSSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 203 RUSSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 204 RUSSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 205 RUSSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 206 RUSSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 207 RUSSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 208 RUSSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 209 RUSSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 210 RUSSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 211 RUSSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 212 NETHERLANDS INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 213 NETHERLANDS INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 214 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 215 NETHERLANDS QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 216 NETHERLANDS TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 217 NETHERLANDS BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 218 NETHERLANDS MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 219 NETHERLANDS VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 220 NETHERLANDS INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 221 NETHERLANDS LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 222 NETHERLANDS DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 223 NETHERLANDS INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 224 NETHERLANDS INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 225 NETHERLANDS INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 226 NETHERLANDS INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 227 NETHERLANDS RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 TURKEY INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 TURKEY INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 230 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 231 TURKEY QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 232 TURKEY TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 233 TURKEY BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 234 TURKEY MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 235 TURKEY VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 236 TURKEY INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 237 TURKEY LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 238 TURKEY DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 239 TURKEY INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 240 TURKEY INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 241 TURKEY INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 242 TURKEY INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 243 TURKEY RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 244 SWITZERLAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 SWITZERLAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 246 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 247 SWITZERLAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 248 SWITZERLAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 249 SWITZERLAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 250 SWITZERLAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 251 SWITZERLAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 252 SWITZERLAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 253 SWITZERLAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 254 SWITZERLAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 255 SWITZERLAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 256 SWITZERLAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 257 SWITZERLAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 258 SWITZERLAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 259 SWITZERLAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 260 BELGIUM INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 261 BELGIUM INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 262 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 263 BELGIUM QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 264 BELGIUM TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 265 BELGIUM BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 266 BELGIUM MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 267 BELGIUM VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 268 BELGIUM INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 269 BELGIUM LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 270 BELGIUM DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 271 BELGIUM INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 272 BELGIUM INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 273 BELGIUM INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 274 BELGIUM INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 275 BELGIUM RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 276 REST OF EUROPE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 278 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 279 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 280 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 281 ASIA-PACIFIC QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 282 ASIA-PACIFIC TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 283 ASIA-PACIFIC BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 284 ASIA-PACIFIC MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 285 ASIA-PACIFIC VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 286 ASIA-PACIFIC INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 287 ASIA-PACIFIC LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 288 ASIA-PACIFIC DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 289 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 290 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 291 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 292 ASIA-PACIFIC INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 293 ASIA-PACIFIC RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 294 JAPAN INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 JAPAN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 296 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 297 JAPAN QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 298 JAPAN TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 299 JAPAN BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 300 JAPAN MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 301 JAPAN VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 302 JAPAN INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 303 JAPAN LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 304 JAPAN DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 305 JAPAN INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 306 JAPAN INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 307 JAPAN INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 308 JAPAN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 309 JAPAN RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 310 CHINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 311 CHINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 312 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 313 CHINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 314 CHINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 315 CHINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 316 CHINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 317 CHINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 318 CHINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 319 CHINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 320 CHINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 321 CHINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 322 CHINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 323 CHINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 324 CHINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 325 CHINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 326 SOUTH KOREA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 327 SOUTH KOREA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 328 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 329 SOUTH KOREA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 330 SOUTH KOREA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 331 SOUTH KOREA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 332 SOUTH KOREA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 333 SOUTH KOREA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 334 SOUTH KOREA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 335 SOUTH KOREA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 336 SOUTH KOREA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 337 SOUTH KOREA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 338 SOUTH KOREA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 339 SOUTH KOREA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 340 SOUTH KOREA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 341 SOUTH KOREA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 342 INDIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 343 INDIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 344 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 345 INDIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 346 INDIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 347 INDIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 348 INDIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 349 INDIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 350 INDIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 351 INDIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 352 INDIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 353 INDIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 354 INDIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 355 INDIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 356 INDIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 357 INDIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 358 AUSTRALIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 AUSTRALIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 360 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 361 AUSTRALIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 362 AUSTRALIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 363 AUSTRALIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 364 AUSTRALIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 365 AUSTRALIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 366 AUSTRALIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 367 AUSTRALIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 368 AUSTRALIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 369 AUSTRALIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 370 AUSTRALIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 371 AUSTRALIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 372 AUSTRALIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 373 AUSTRALIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 374 MALAYSIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 375 MALAYSIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 376 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 377 MALAYSIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 378 MALAYSIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 379 MALAYSIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 380 MALAYSIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 381 MALAYSIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 382 MALAYSIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 383 MALAYSIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 384 MALAYSIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 385 MALAYSIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 386 MALAYSIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 387 MALAYSIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 388 MALAYSIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 389 MALAYSIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 390 THAILAND INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 391 THAILAND INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 392 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 393 THAILAND QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 394 THAILAND TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 395 THAILAND BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 396 THAILAND MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 397 THAILAND VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 398 THAILAND INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 399 THAILAND LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 400 THAILAND DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 401 THAILAND INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 402 THAILAND INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 403 THAILAND INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 404 THAILAND INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 405 THAILAND RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 406 INDONESIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 407 INDONESIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 408 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 409 INDONESIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 410 INDONESIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 411 INDONESIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 412 INDONESIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 413 INDONESIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 414 INDONESIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 415 INDONESIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 416 INDONESIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 417 INDONESIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 418 INDONESIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 419 INDONESIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 420 INDONESIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 421 INDONESIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 422 SINGAPORE INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 423 SINGAPORE INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 424 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 425 SINGAPORE QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 426 SINGAPORE TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 427 SINGAPORE BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 428 SINGAPORE MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 429 SINGAPORE VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 430 SINGAPORE INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 431 SINGAPORE LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 432 SINGAPORE DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 433 SINGAPORE INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 434 SINGAPORE INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 435 SINGAPORE INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 436 SINGAPORE INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 437 SINGAPORE RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 438 PHILIPPINES INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 439 PHILIPPINES INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 440 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 441 PHILIPPINES QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 442 PHILIPPINES TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 443 PHILIPPINES BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 444 PHILIPPINES MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 445 PHILIPPINES VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 446 PHILIPPINES INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 447 PHILIPPINES LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 448 PHILIPPINES DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 449 PHILIPPINES INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 450 PHILIPPINES INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 451 PHILIPPINES INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 452 PHILIPPINES INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 453 PHILIPPINES RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 454 REST OF ASIA-PACIFIC INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 455 SOUTH AMERICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 456 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 457 SOUTH AMERICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 458 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 459 SOUTH AMERICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 460 SOUTH AMERICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 461 SOUTH AMERICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 462 SOUTH AMERICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 463 SOUTH AMERICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 464 SOUTH AMERICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 465 SOUTH AMERICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 466 SOUTH AMERICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 467 SOUTH AMERICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 468 SOUTH AMERICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 469 SOUTH AMERICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 470 SOUTH AMERICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 471 SOUTH AMERICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 472 BRAZIL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 473 BRAZIL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 474 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 475 BRAZIL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 476 BRAZIL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 477 BRAZIL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 478 BRAZIL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 479 BRAZIL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 480 BRAZIL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 481 BRAZIL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 482 BRAZIL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 483 BRAZIL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 484 BRAZIL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 485 BRAZIL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 486 BRAZIL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 487 BRAZIL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 488 ARGENTINA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 489 ARGENTINA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 490 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 491 ARGENTINA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 492 ARGENTINA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 493 ARGENTINA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 494 ARGENTINA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 495 ARGENTINA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 496 ARGENTINA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 497 ARGENTINA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 498 ARGENTINA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 499 ARGENTINA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 500 ARGENTINA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 501 ARGENTINA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 502 ARGENTINA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 503 ARGENTINA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 504 REST OF SOUTH AMERICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 505 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 506 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 507 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 508 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 509 MIDDLE EAST AND AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 510 MIDDLE EAST AND AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 511 MIDDLE EAST AND AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 512 MIDDLE EAST AND AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 513 MIDDLE EAST AND AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 514 MIDDLE EAST AND AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 515 MIDDLE EAST AND AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 516 MIDDLE EAST AND AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 517 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 518 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 519 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 520 MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 521 MIDDLE EAST AND AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 522 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 523 SOUTH AFRICA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 524 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 525 SOUTH AFRICA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 526 SOUTH AFRICA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 527 SOUTH AFRICA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 528 SOUTH AFRICA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 529 SOUTH AFRICA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 530 SOUTH AFRICA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 531 SOUTH AFRICA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 532 SOUTH AFRICA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 533 SOUTH AFRICA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 534 SOUTH AFRICA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 535 SOUTH AFRICA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 536 SOUTH AFRICA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 537 SOUTH AFRICA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 538 U.A.E. INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 539 U.A.E. INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 540 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 541 U.A.E. QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 542 U.A.E. TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 543 U.A.E. BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 544 U.A.E. MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 545 U.A.E. VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 546 U.A.E. INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 547 U.A.E. LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 548 U.A.E. DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 549 U.A.E. INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 550 U.A.E. INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 551 U.A.E. INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 552 U.A.E. INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 553 U.A.E. RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 554 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 555 SAUDI ARABIA INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 556 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 557 SAUDI ARABIA QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 558 SAUDI ARABIA TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 559 SAUDI ARABIA BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 560 SAUDI ARABIA MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 561 SAUDI ARABIA VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 562 SAUDI ARABIA INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 563 SAUDI ARABIA LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 564 SAUDI ARABIA DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 565 SAUDI ARABIA INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 566 SAUDI ARABIA INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 567 SAUDI ARABIA INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 568 SAUDI ARABIA INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 569 SAUDI ARABIA RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 570 EGYPT INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 571 EGYPT INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 572 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 573 EGYPT QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 574 EGYPT TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 575 EGYPT BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 576 EGYPT MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 577 EGYPT VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 578 EGYPT INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 579 EGYPT LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 580 EGYPT DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 581 EGYPT INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 582 EGYPT INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 583 EGYPT INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 584 EGYPT INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 585 EGYPT RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 586 ISRAEL INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 587 ISRAEL INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 588 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 589 ISRAEL QUADRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 590 ISRAEL TRIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 591 ISRAEL BIVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 592 ISRAEL MONOVALENT IN INFLUENZA DRUG MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 593 ISRAEL VACCINES IN INFLUENZA DRUG MARKET, BY TECHNOLOGY, 2022-2031 (USD THOUSAND)
TABLE 594 ISRAEL INACTIVATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 595 ISRAEL LIVE ATTENUATED IN INFLUENZA DRUG MARKET, BY VALENCY, 2022-2031 (USD THOUSAND)
TABLE 596 ISRAEL DRUGS IN INFLUENZA DRUG MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 597 ISRAEL INFLUENZA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 598 ISRAEL INFLUENZA DRUG MARKET, BY AGE, 2022-2031 (USD THOUSAND)
TABLE 599 ISRAEL INFLUENZA DRUG MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 600 ISRAEL INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 601 ISRAEL RETAIL SALES IN INFLUENZA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 602 REST OF MIDDLE EAST AND AFRICA INFLUENZA DRUG MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 GLOBAL INFLUENZA DRUG MARKET: SEGMENTATION
FIGURE 2 GLOBAL INFLUENZA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL INFLUENZA DRUG MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL INFLUENZA DRUG MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL INFLUENZA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL INFLUENZA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL INFLUENZA DRUG MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL INFLUENZA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL INFLUENZA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL INFLUENZA DRUG MARKET: SEGMENTATION
FIGURE 11 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS IS DRIVING THE GROWTH OF THE GLOBAL INFLUENZA DRUG MARKET FROM 2024 TO 2031
FIGURE 12 THE INFLUENZA A SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INFLUENZA DRUG MARKET IN 2024 AND 2031
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INFLUENZA DRUG MARKET AND ALSO NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR INFLUENZA DRUG MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL INFLUENZA DRUGS MARKET
FIGURE 16 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, 2023
FIGURE 17 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 18 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 19 GLOBAL INFLUENZA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, 2023
FIGURE 21 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 22 GLOBAL INFLUENZA DRUG MARKET: BY CAGR (2024-2031)
FIGURE 23 GLOBAL INFLUENZA DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, 2023
FIGURE 25 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 26 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 27 GLOBAL INFLUENZA DRUG MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 GLOBAL INFLUENZA DRUG MARKET : BY AGE, 2023
FIGURE 29 GLOBAL INFLUENZA DRUG MARKET : BY AGE, 2024-2031 (USD THOUSAND)
FIGURE 30 GLOBAL INFLUENZA DRUG MARKET : BY AGE, CAGR (2024-2031)
FIGURE 31 GLOBAL INFLUENZA DRUG MARKET : BY AGE, LIFELINE CURVE
FIGURE 32 GLOBAL INFLUENZA DRUG MARKET : BY END USER, 2023
FIGURE 33 GLOBAL INFLUENZA DRUG MARKET : BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 34 GLOBAL INFLUENZA DRUG MARKET : BY END USER, CAGR (2024-2031)
FIGURE 35 GLOBAL INFLUENZA DRUG MARKET : BY END USER, LIFELINE CURVE
FIGURE 36 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 37 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 38 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 39 GLOBAL INFLUENZA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 GLOBAL INFLUENZA DRUG MARKET: SNAPSHOT (2023)
FIGURE 41 GLOBAL INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 42 NORTH AMERICA INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 43 EUROPE INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
FIGURE 44 AISA-PACIFIC INFLUENZA DRUG MARKET: COMPANY SHARE 2023 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
